|
|
|
|
|
Triprolidine
drug data and news
Triprolidine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Triprolidine | ||
| Brand Names/Synonyms | Actidil; Myidyl; Triprolidin; Triprolidine; Triprolidine Hcl; Triprolidine Hydrochloride; Tripyrolidine | ||
| Indication | For the treatment of hay fever, urticaria (hives), and other allergic systems. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Triprolidine, is a histamine H1 antagonist that competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies. | ||
| Mechanism Of Action | Triprolidine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. | ||
| Triprolidine News (When available) |
| ||
| Dosage Forms | Syrup; Tablets | ||
| Drug_Category | Anti-allergic Agents; ATC:R06AX07 | ||
| Absorption | Rapidly absorbed in the intestinal tract. | ||
| Interactions |
Interactions for Triprolidine: Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. Triprolidine may effect the metabolism of drugs in the liver. | ||
| Toxicity | Symptoms of overdose include drowsiness, weakness, inco-ordination, difficulty with micturition, respiratory depression, hypotension, agitation, irritability, convulsions, hypertension, palpitation and tachycardia. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 2-[1-(4-methylphenyl)-3-pyrrolidin-1-yl-prop-1-enyl]pyridine | ||
| Chemical Formula | C19H22N2 | ||
| Molecular Weight | 278.391 g/mol | ||
| Smiles String | CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC=N3 | ||
| Melting Point | 60 °C | ||
| Water Solubility | 74.9 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 3.729 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 4 to 6 hours. | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.drugs.com/cons/Triprolidine.html | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00306 | ||
| CAS Registry Number | 486-12-4 | ||
| KEGG Compound ID | D01782 | ||
| PubChem ID | SID:362852 | ||
| PharmGKB ID | PA451797 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |